Statins and all-cause mortality in high-risk primary prevention

Statins and all-cause mortality in high-risk primary prevention

Article Type: Reviews of effectiveness From: Clinical Governance: An International Journal, Volume 15, Issue 4

Ray, K.K., Seshasai, S.R., Erqou, S., Sever, P., Jukema, W., Ford, I. and Sattar, N.,Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants,Archives of Internal Medicine,2010,Vol. 170,pp. 1024-1031

The authors concluded that statin therapy for an average period of 3.7 years did not significantly reduce all-cause mortality in a high-risk primary prevention population. The authors acknowledged certain limitations with the included trials and statistical analyses. Despite the potential for bias in the review, the authors’ conclusions appear to reflect the evidence, based on a large sample population.